Trandate

Labetalol HCl

Tab: Mild, moderate or severe HTN; HTN in pregnancy; angina pectoris w/ coexisting HTN. Inj: Severe HTN including severe HTN in pregnancy when rapid BP control is essential; controlled hypotension during anaesth.

Tab Mild, moderate or severe HTN & angina pectoris w/ coexisting HTN Initially 100 mg bd, increase at intervals of 2-14 days. Severe, refractory HTN 2,400 mg daily in 3 or 4 divided doses. HTN in pregnancy Initially 100 mg bd, increase at wkly intervals. Max total dose: 2,400 mg daily. Adult Severe HTN Bolus inj 50 mg IV for at least 1 min. If necessary, repeat at 5-min intervals until satisfactory response occurs. Max total dose: 200 mg. IV infusion 160 mg/hr, adjusted individually. Dose range: 50-200 mg until satisfactory response is obtained. Severe HTN in pregnancy IV infusion Start infusion at rate of 20 mg/hr & doubled every 30 min until satisfactory response is obtained or 160 mg/hr is reached. Hypotensive anaesth 10-20 mg IV, 5-10 mg increments may be given until desired BP is achieved. HTN due to other causes 120-160 mg/hr until satisfactory response is obtained. Dose range: 50-200 mg.

Should be taken with food.

Hypersensitivity. Asthma or history of obstructive airway disease; 2nd- or 3rd-degree heart block, cardiogenic shock, severe & prolonged hypotension or bradycardia; uncompensated heart failure; unstable/uncontrolled heart insufficiency; sick sinus syndrome including sinus atrial block unless pacemaker in situ; Prinzmetal angina; sinus node dysfunction.

Discontinue use if evidence of liver injury or jaundice is present. History of severe anaphylactic reaction. Peripheral arterial disease (Raynaud's syndrome, intermittent claudication); symptomatic bradycardia; 1st-degree AV block; skin rashes, dry eyes; intraoperative floppy iris syndrome; heart failure or poor left ventricular systolic function, reduced contractility; metabolic acidosis, pheochromocytoma. May mask symptoms of hypoglycaemia & thyrotoxicosis. Avoid abrupt w/drawal. Gradually decrease if co-administered w/ other hypotensives eg, diuretics, methyldopa. Concomitant use w/ adrenaline, inhalation anaesth, Ca antagonists, verapamil or Class I antiarrhythmics. Hepatic impairment. Severe renal impairment (GFR 15-29 mL/min/1.73 m²). Pregnancy & lactation. Paed 0-18 yr. Elderly. Tab: Ischaemic heart disease. May affect ability to drive & operate machines. Inj: May mask compensatory physiological responses of sudden haemorrhage. Avoid raising patient into upright position during infusion.

Hypersensitivity, drug fever; CHF; postural hypotension; nasal congestion; raised LFTs; erectile dysfunction. Tab: Positive ANA unassociated w/ disease. Lichenoid rash; dizziness, headache, tingling sensation in scalp; blurred vision; nausea; difficulty in micturition; ejaculatory failure; tiredness, lethargy.

Reduced hypotensive effect w/ prostaglandin synthetase inhibitors eg, NSAIDs. Additive synergism w/ other antihypertensives. Reduced uptake of metaiodobenzylguanidine radioisotopes. Increased risk of hypotension w/ dihydropyridine Ca antagonists eg, nifedipine. Enhanced digoxin effect in reducing ventricular rate. Bradycardia & HTN w/ adrenaline, Ca antagonists w/ -ve inotropic effect eg, verapamil, diltiazem. Increased risk of myocardial depression w/ class I (eg, disopyramide, quinidine) & class II (eg, amiodarone) antiarrhythmics. Increased risk of hypoglycemia w/ oral antidiabetics & insulin. Reduced reflectoric tachycardia & risk of hypotension w/ general anaesth. Rebound hypertensive crisis w/ clonidine. Increased risk of bradycardia w/ cholinesterase inhibitors. Increased risk of increased BP w/ α-stimulating adrenergics eg, phenylpropanolamine, adrenaline. Increased risk of vasospastic reactions w/ ergotamine derivates. Increased effect of imipramine. Increased incidence of tremor w/ TCAs. Interference w/ assays of certain fluorescent substances including catecholamines. Tab: Increased bioavailability w/ cimetidine. Enhanced BP reduction w/ nitrates, antipsychotics (phenothiazine derivates eg, chlorpromazine), other antipsychotics, antidepressants. Inj: Enhanced hypotensive effects of volatile anaesth.

Beta-Blockers

C07AG01 - labetalol ; Belongs to the class of alpha and beta blocking agents. Used in the treatment of cardiovascular diseases.

B